Focus: Alliance Pharmaceuticals is a UK-based specialty pharma company focused on acquisition and licensing of established and pipeline assets, operating at mid-cap scale with 201-500 employees. The company concentrates on neurology and oncology therapeutics through a portfolio of licensed and acquired programs.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Alliance is a specialized acquisition-and-licensing play with clinical pipeline depth but opaque financials and no current hiring—suitable for acquisition strategy experts or late-stage development specialists willing to tolerate uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Sole marketed product with approaching loss of exclusivity; limited revenue contribution to portfolio.
Help build intelligence for Alliance Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Alliance Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen(®) and Smart B(®) in Women with Climacteric Syndrome in Perimenopause.
Immunologic control of tumors by in vivo Fc gamma receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo